» Articles » PMID: 14963122

Expansion of Protective CD8+ T-cell Responses Driven by Recombinant Cytomegaloviruses

Overview
Journal J Virol
Date 2004 Feb 14
PMID 14963122
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

CD8(+) T cells are critical for the control of many persistent viral infections, such as human immunodeficiency virus, hepatitis C virus, Epstein-Barr virus, and cytomegalovirus (CMV). In most infections, large CD8(+)-T-cell populations are induced early but then contract and are maintained thereafter at lower levels. In contrast, CD8(+) T cells specific for murine CMV (MCMV) have been shown to gradually accumulate after resolution of primary infection. This unique behavior is restricted to certain epitopes, including an immunodominant epitope derived from the immediate-early 1 (IE1) gene product. To explore the mechanism behind this further, we measured CD8(+)-T-cell-mediated immunity induced by recombinant MCMV-expressing epitopes derived from influenza A virus or lymphocytic choriomeningitis virus placed under the control of an IE promoter. We observed that virus-specific CD8(+)-T-cell populations were induced and that these expanded gradually over time. Importantly, these CD8(+) T cells provided long-term protection against challenge without boosting. These results demonstrate a unique pattern of accumulating T cells, which provide long-lasting immune protection, that is independent of the initial immunodominance of the epitope and indicates the potential of T-cell-inducing vaccines based on persistent vectors.

Citing Articles

A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants.

Metzdorf K, Jacobsen H, Kim Y, Teixeira Alves L, Kulkarni U, Cokaric Brdovcak M Front Immunol. 2024; 15:1383086.

PMID: 39119342 PMC: 11306140. DOI: 10.3389/fimmu.2024.1383086.


Cytomegalovirus immunity in high-risk liver transplant recipients following preemptive antiviral therapy versus prophylaxis.

Zamora D, Dasgupta S, Stevens-Ayers T, Edmison B, Winston D, Razonable R JCI Insight. 2024; 9(18).

PMID: 39099206 PMC: 11457861. DOI: 10.1172/jci.insight.180115.


Construction and Characterization of a High-Capacity Replication-Competent Murine Cytomegalovirus Vector for Gene Delivery.

Riedl A, Bojkova D, Tan J, Jeney A, Larsen P, Jeney C Vaccines (Basel). 2024; 12(7).

PMID: 39066429 PMC: 11281640. DOI: 10.3390/vaccines12070791.


Memory inflation: Beyond the acute phase of viral infection.

Li Y, Xiao J, Li C, Yang M Cell Prolif. 2024; 57(12):e13705.

PMID: 38992867 PMC: 11628752. DOI: 10.1111/cpr.13705.


Transcriptional signature of durable effector T cells elicited by a replication defective HCMV vaccine.

Ye X, Shih D, Ku Z, Hong J, Barrett D, Rupp R NPJ Vaccines. 2024; 9(1):70.

PMID: 38561339 PMC: 10984989. DOI: 10.1038/s41541-024-00860-w.


References
1.
Swain S, Hu H, Huston G . Class II-independent generation of CD4 memory T cells from effectors. Science. 1999; 286(5443):1381-3. DOI: 10.1126/science.286.5443.1381. View

2.
Reddehase M, Balthesen M, Rapp M, Jonjic S, Pavic I, Koszinowski U . The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med. 1994; 179(1):185-93. PMC: 2191331. DOI: 10.1084/jem.179.1.185. View

3.
Altman J, Moss P, Goulder P, Barouch D, McHeyzer-Williams M, Bell J . Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996; 274(5284):94-6. DOI: 10.1126/science.274.5284.94. View

4.
Hengel H, Reusch U, Geginat G, Holtappels R, Ruppert T, Hellebrand E . Macrophages escape inhibition of major histocompatibility complex class I-dependent antigen presentation by cytomegalovirus. J Virol. 2000; 74(17):7861-8. PMC: 112316. DOI: 10.1128/jvi.74.17.7861-7868.2000. View

5.
Del Val M, Munch K, Reddehase M, Koszinowski U . Presentation of CMV immediate-early antigen to cytolytic T lymphocytes is selectively prevented by viral genes expressed in the early phase. Cell. 1989; 58(2):305-15. DOI: 10.1016/0092-8674(89)90845-3. View